Cassava Sciences reported $-9.39M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Abbott USD 1.36B 775M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cassava Sciences USD -9.39M 1.78M Jun/2026
Eisai JPY 16.7B 8.03B Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Geron USD 5.73M 18.38M Sep/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 392M Sep/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 662M 5M Sep/2026
Roche Holding CHF 11.46B 1.91B Jun/2026